Around the world over thousands of years, patients have received root-cause holistic treatment for their diseases with personalized
treatment, diet and lifestyle modification recommendations. Read the inspiring true stories of practitioners who heal people and who recovered
from their problems after autism-spectrum-disorders treatment at their clinics. Many have been generous to share their knowledge and experience for the benefit
of other holistic experts and patients alike. Many practitioners share their Case Studies and the healing powers of autism-spectrum-disorders and related therapies
as they heal people who benefited from our expertise.
Sulforaphane treatment of autism spectrum disorder (ASD).
October 2014
/ onclick=”MoreLine(‘11148’, ‘Sulforaphane treatment of autism spectrum disorder (ASD).’)”>
…more
/>Proc Natl Acad Sci U S A. 2014 Oct 28 ;111(43):15550-5. Epub 2014 Oct 13. PMID: 25313065
Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism.
May 2010
The study objectives were to determine whether methyl B12 treatment improves behavioral measures in children with autism and whether improvement is associated with increased plasma concentrations of glutathione (GSH) and an increased redox ratio of reduced glutathione to oxidized glutathione (GSH/GSSG), both of which have been previously identified to be low in children with autism.
DESIGN:
This was a 12-week, double-blind, placebo-controlled, cross-over clinical trial of injectable methyl B12. Following this 12-week study, subjects were given the option of entering a 6-month open-label trial of methyl B12. SETTINGS/LOCATION: All procedures took place at the UC Davis M.I.N.D. Institute.
SUBJECTS:
Subjects were 3 to 8 years old with autism. INTERVENTIONS: All subjects received 6 weeks of placebo and 6 weeks of methyl B12 at a dose of 64.5 mcg/kg every three days administered subcutaneously into the buttocks. OUTCOME MEASURES: Blood for GSH analysis and behavioral assessments were obtained at baseline, week 6, and week 12.
Results:
Thirty (30) subjects completed the 12-week, double-blind study and 22 subjects completed the 6-month extension study. No statistically significant mean differences in behavior tests or in glutathione status were identified between active and placebo groups. Nine (9) subjects (30%) demonstrated clinically significant improvement on the Clinical Global Impression Scale and at least two additional behavioral measures. More notably, these responders exhibited significantly increased plasma concentrations of GSH and GSH/GSSG. CONCLUSIONS: Comparison of the overall means between groups suggests that methyl B12 is ineffective in treating behavioral symptoms of autism. However, detailed data analysis suggests that methyl B12 may alleviate symptoms of autism in a subgroup of children, possibly by reducing oxidative stress. An increase in glutathione redox status (GSH/GSSG) may provide a biomarker for treatment response to methyl B12. Additional research is needed to delineate a subgroup of potential responders and ascertain a biomarker for response to methyl B12.
/ onclick=”MoreLine(‘11147’, ‘Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism.’)”>
…more
/>J Altern Complement Med. 2010 May;16(5):555-60. PMID: 20804367
Antidepressant Use During Pregnancy and the Risk of Autism Spectrum Disorder in Children.
January 2016
To examine the risk of ASD in children associated with antidepressant use during pregnancy according to trimester of exposure and taking into account maternal depression. DESIGN, SETTING, AND PARTICIPANTS: We conducted a register-based study of an ongoing population-based cohort, the Québec Pregnancy/Children Cohort, which includes data on all pregnancies and children in Québec from January 1, 1998, to December 31, 2009. A total of 145,456 singleton full-term infants born alive and whose mothers were covered by the Régie de l’assurance maladie du Québec drug plan for at least12 months before and during pregnancy were included. Data analysis was conducted from October 1, 2014, to June 30, 2015. EXPOSURES: Antidepressant exposure during pregnancy was defined according to trimester and specific antidepressant classes. MAIN OUTCOMES AND MEASURES: Children with ASD were defined as those with at least 1 diagnosis of ASD between date of birth and last date of follow-up. Cox proportional hazards regression models were used to estimate crude and adjusted hazard ratios with 95% CIs.
Results:
During 904,035.50 person-years of follow-up, 1054 children (0.7%) were diagnosed with ASD; boys with ASD outnumbered girls by a ratio of about 4:1. The mean (SD) age of children at the end of follow-up was 6.24 (3.19) years. Adjusting for potential confounders, use of antidepressants during the second and/or third trimester was associated with the risk of ASD (31 exposed infants; adjusted hazard ratio, 1.87; 95% CI, 1.15-3.04). Use of selective serotonin reuptake inhibitors during the second and/or third trimester was significantly associated with an increased risk of ASD (22 exposed infants; adjusted hazard ratio, 2.17; 95% CI, 1.20-3.93). The risk was persistent even after taking into account maternal history of depression (29 exposed infants; adjusted hazard ratio, 1.75; 95% CI, 1.03-2.97). CONCLUSIONS AND RELEVANCE: Use of antidepressants, specifically selective serotonin reuptake inhibitors, during the second and/or third trimester increases the risk of ASD in children, even after considering maternal depression. Further research is needed to specifically assess the risk of ASD associated with antidepressant types and dosages during pregnancy.
/ onclick=”MoreLine(‘11146’, ‘Antidepressant Use During Pregnancy and the Risk of Autism Spectrum Disorder in Children.’)”>
…more
/>JAMA Pediatr. 2016 Feb ;170(2):117-24. PMID: 26660917
Bisphenol A Exposure in Children With Autism Spectrum Disorders.
May 2015
/ onclick=”MoreLine(‘11145’, ‘Bisphenol A Exposure in Children With Autism Spectrum Disorders.’)”>
…more
/>Autism Res. 2015 Jun ;8(3):272-83. Epub 2015 Jan 13. PMID: 25641946
A Randomized Controlled Pilot Trial of Oral N-Acetylcysteine in Children with Autism.
February 2012
An imbalance in the excitatory/inhibitory systems with abnormalities in the glutamatergic pathways has been implicated in the pathophysiology of autism. Furthermore, chronic redox imbalance was also recently linked to this disorder. The goal of this pilot study was to assess the feasibility of using oral N-acetylcysteine (NAC), a glutamatergic modulator and an antioxidant, in the treatment of behavioral disturbance in children with autism.
METHODS:
This was a 12-week, double-blind, randomized, placebo-controlled study of NAC in children with autistic disorder. Subjects randomized to NAC were initiated at 900 mg daily for 4 weeks, then 900 mg twice daily for 4 weeks and 900 mg three times daily for 4 weeks. The primary behavioral measure (Aberrant Behavior Checklist [ABC] irritability subscale) and safety measures were performed at baseline and 4, 8, and 12 weeks. Secondary measures included the ABC stereotypy subscale, Repetitive Behavior Scale-Revised, and Social Responsiveness Scale.
Results:
Thirty-three subjects (31 male subjects, 2 female subjects; aged 3.2-10.7 years) were randomized in the study. Follow-up data was available on 14 subjects in the NAC group and 15 in the placebo group. Oral NAC was well tolerated with limited side effects. Compared with placebo, NAC resulted in significant improvements on ABC irritability subscale (F = 6.80; p
/ onclick=”MoreLine(‘11144’, ‘A Randomized Controlled Pilot Trial of Oral N-Acetylcysteine in Children with Autism.’)”>
…more
/>Biol Psychiatry. 2012 Feb 17. Epub 2012 Feb 17. PMID: 22342106
A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities.
January 2008
/ onclick=”MoreLine(‘11143’, ‘A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities.’)”>
…more
/>J Pineal Res. 2008 Jan;44(1):57-64. PMID: 18078449